Product

TAS1440 + ATRA

1 clinical trial

1 indication

Indication

Acute Myeloid Leukemia

Clinical trial

A Phase 1 Study of Safety, Pharmacokinetics, and Preliminary Activity of TAS1440, as a Single Agent and in Combination With All-Trans Retinoic Acid (ATRA) in Subjects With Relapsed or Refractory (r/r) Acute Myeloid Leukemia (AML)

Status: Active (not recruiting), Estimated PCD: 2025-12-01